Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 8, 2013PLoS ONEOpen Access

Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

EBErica L. Bradshaw‐PiercePfizer (United States)TPTodd M. PittsThe Medical Center of AuroraGKGillian N. KulikowskiBeth Israel Deaconess Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Bradshaw‐Pierce et al. (2013) studied this question.

synapsesocial.com/papers/6a75162f0081fe7b05dc02b7https://doi.org/10.1371/journal.pone.0058089
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1High Frequency of Mutations of the <i>PIK3CA</i> Gene in Human Cancers2004 · 3,477 citations
  2. 2Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors2009 · 75 citations